Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
- Conditions
- Meningioma of Brain
- Registration Number
- NCT06614205
- Lead Sponsor
- Central Hospital, Nancy, France
- Brief Summary
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
- Detailed Description
Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
- patients treated for menigioma at nancy hospital
- patients who performed 3 scintigraphics exams during there treatment
- patients deprived of liberty
- patient who refused to collect data retrospectively
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic accuracy for progression free survival Day 1 Accuracy of tumor dosimetry to predict 6-month progression-free survival.
- Secondary Outcome Measures
Name Time Method Diagnostic accuracy for overal survival Day 1 Accuracy of tumoral dosimetry in predicting 6-month overall survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
CHRU de NANCY
🇫🇷Vandoeuvre les Nancy cedex, France
Nuclear medicine Department CHRU de NANCY
🇫🇷Vandoeuvre les Nancy cedex, France
CHRU de NANCY🇫🇷Vandoeuvre les Nancy cedex, France